{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:38:41Z","timestamp":1791362321361,"version":"4.3.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MBF Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00262-018-2201-5","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T08:25:17Z","timestamp":1532593517000},"page":"1533-1544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma"],"prefix":"10.1007","volume":"67","author":[{"given":"Raj K.","family":"Kurupati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine H.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-5206","authenticated-orcid":false,"given":"Hildegund C. J.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"2201_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1939-1676.2008.0133.x","volume":"22","author":"DF Merlo","year":"2008","unstructured":"Merlo DF, Rossi L, Pellegrino C et al (2008) Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 22:976\u2013984. https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0133.x","journal-title":"J Vet Intern Med"},{"key":"2201_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/pcmr.12185","volume":"27","author":"RM Simpson","year":"2014","unstructured":"Simpson RM, Bastian BC, Michael HT et al (2014) Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res 27:37\u201347. https:\/\/doi.org\/10.1111\/pcmr.12185","journal-title":"Pigment Cell Melanoma Res"},{"key":"2201_CR3","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2460\/javma.245.11.1266","volume":"245","author":"JL Tuohy","year":"2014","unstructured":"Tuohy JL, Selmic LE, Worley DR et al (2014) Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998\u20132011). J Am Vet Med Assoc 245:1266\u20131273. https:\/\/doi.org\/10.2460\/javma.245.11.1266","journal-title":"J Am Vet Med Assoc"},{"key":"2201_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2460\/ajvr.72.12.1631","volume":"72","author":"DA Grosenbaugh","year":"2011","unstructured":"Grosenbaugh DA, Leard AT, Bergman PJ et al (2011) Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72:1631\u20131638. https:\/\/doi.org\/10.2460\/ajvr.72.12.1631","journal-title":"Am J Vet Res"},{"key":"2201_CR5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2460\/javma.247.10.1146","volume":"247","author":"M Kawabe","year":"2015","unstructured":"Kawabe M, Mori T, Ito Y et al (2015) Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006\u20132012). J Am Vet Med Assoc 247:1146\u20131153. https:\/\/doi.org\/10.2460\/javma.247.10.1146","journal-title":"J Am Vet Med Assoc"},{"key":"2201_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2460\/javma.2004.224.388","volume":"224","author":"PA Boria","year":"2004","unstructured":"Boria PA, Murry DJ, Bennett PF et al (2004) Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 224:388\u2013394","journal-title":"J Am Vet Med Assoc"},{"key":"2201_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/02656738509029287","volume":"1","author":"MW Dewhirst","year":"1985","unstructured":"Dewhirst MW, Sim DA, Forsyth K et al (1985) Local control and distant metastases in primary canine malignant melanomas treated with hyperthermia and\/or radiotherapy. Int J Hyperth 1:219\u2013234. https:\/\/doi.org\/10.3109\/02656738509029287","journal-title":"Int J Hyperth"},{"key":"2201_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1354\/vp.45-6-889","volume":"45","author":"DG Esplin","year":"2008","unstructured":"Esplin DG (2008) Survival of dogs following surgical excision of histologically well-differentiated melanocytic neoplasms of the mucous membranes of the lips and oral cavity. Vet Pathol 45:889\u2013896. https:\/\/doi.org\/10.1354\/vp.45-6-889","journal-title":"Vet Pathol"},{"key":"2201_CR9","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.2460\/javma.242.10.1392","volume":"242","author":"WTN Culp","year":"2013","unstructured":"Culp WTN, Ehrhart N, Withrow SJ et al (2013) Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995\u20132008). J Am Vet Med Assoc 242:1392\u20131397. https:\/\/doi.org\/10.2460\/javma.242.10.1392","journal-title":"J Am Vet Med Assoc"},{"key":"2201_CR10","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4. https:\/\/doi.org\/10.1126\/scitranslmed.aad7118","journal-title":"Sci Transl Med"},{"key":"2201_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/imt.14.9","volume":"6","author":"KA Reiss","year":"2014","unstructured":"Reiss KA, Forde PM, Brahmer JR (2014) Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy 6:459\u2013475. https:\/\/doi.org\/10.2217\/imt.14.9","journal-title":"Immunotherapy"},{"key":"2201_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, Somerville RPT, Yang JC et al (2017) Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol 18:792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6","journal-title":"Lancet Oncol"},{"key":"2201_CR13","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, Zhao Y, Levine BL et al (2017) Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 5:1152\u20131161. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0189","journal-title":"Cancer Immunol Res"},{"key":"2201_CR14","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1080\/21645515.2015.1062190","volume":"11","author":"DG McNeel","year":"2015","unstructured":"McNeel DG, Chen Y-H, Gulley JL et al (2015) Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: a trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccines Immunother 11:2469\u20132474. https:\/\/doi.org\/10.1080\/21645515.2015.1062190","journal-title":"Hum Vaccines Immunother"},{"key":"2201_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","volume":"25","author":"J Crespo","year":"2013","unstructured":"Crespo J, Sun H, Welling TH et al (2013) T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25:214\u2013221. https:\/\/doi.org\/10.1016\/j.coi.2012.12.003","journal-title":"Curr Opin Immunol"},{"key":"2201_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.it.2012.02.006","volume":"33","author":"L Baitsch","year":"2012","unstructured":"Baitsch L, Fuertes-Marraco SA, Legat A et al (2012) The three main stumbling blocks for anticancer T cells. Trends Immunol 33:364\u2013372. https:\/\/doi.org\/10.1016\/j.it.2012.02.006","journal-title":"Trends Immunol"},{"key":"2201_CR17","doi-asserted-by":"publisher","first-page":"e1016700","DOI":"10.1080\/2162402X.2015.1016700","volume":"4","author":"AA Wu","year":"2015","unstructured":"Wu AA, Drake V, Huang H-S et al (2015) Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 4:e1016700. https:\/\/doi.org\/10.1080\/2162402X.2015.1016700","journal-title":"Oncoimmunology"},{"key":"2201_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2017.08.004","volume":"32","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kurupati R, Liu L et al (2017) Enhancing CD8 + T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 32:377\u2013391.e9. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.004","journal-title":"Cancer Cell"},{"key":"2201_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.coi.2015.12.006","volume":"39","author":"PKH Lau","year":"2016","unstructured":"Lau PKH, Ascierto PA, McArthur G (2016) Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Curr Opin Immunol 39:30\u201338. https:\/\/doi.org\/10.1016\/j.coi.2015.12.006","journal-title":"Curr Opin Immunol"},{"key":"2201_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1744666X.2016.1214575","volume":"13","author":"KE Beckermann","year":"2017","unstructured":"Beckermann KE, Johnson DB, Sosman JA (2017) PD-1\/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol 13:77\u201384. https:\/\/doi.org\/10.1080\/1744666X.2016.1214575","journal-title":"Expert Rev Clin Immunol"},{"key":"2201_CR21","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PloS One 11:e0160221. https:\/\/doi.org\/10.1371\/journal.pone.0160221","journal-title":"PloS One"},{"key":"2201_CR22","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.4049\/jimmunol.1302029","volume":"193","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Ertl HCJ (2014) The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8 + T cell exhaustion. J Immunol 193:1836\u20131846. https:\/\/doi.org\/10.4049\/jimmunol.1302029","journal-title":"J Immunol"},{"key":"2201_CR23","doi-asserted-by":"publisher","first-page":"23282","DOI":"10.18632\/oncotarget.7818","volume":"7","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Ertl HCJ (2016) Depletion of FAP + cells reduces immunosuppressive cells and improves metabolism and functions CD8 + T cells within tumors. Oncotarget 7:23282\u201323299. https:\/\/doi.org\/10.18632\/oncotarget.7818","journal-title":"Oncotarget"},{"key":"2201_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0165-2427(93)90075-F","volume":"39","author":"CN Jacobsen","year":"1993","unstructured":"Jacobsen CN, Aasted B, Broe MK, Petersen JL (1993) Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopathol 39:461\u2013466","journal-title":"Vet Immunol Immunopathol"},{"key":"2201_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0165-2427(02)00139-3","volume":"88","author":"LG Pedersen","year":"2002","unstructured":"Pedersen LG, Castelruiz Y, Jacobsen S, Aasted B (2002) Identification of monoclonal antibodies that cross-react with cytokines from different animal species. Vet Immunol Immunopathol 88:111\u2013122","journal-title":"Vet Immunol Immunopathol"},{"key":"2201_CR26","doi-asserted-by":"publisher","first-page":"11603","DOI":"10.1128\/JVI.75.23.11603-11613.2001","volume":"75","author":"SF Farina","year":"2001","unstructured":"Farina SF, Gao GP, Xiang ZQ et al (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75:11603\u201311613. https:\/\/doi.org\/10.1128\/JVI.75.23.11603-11613.2001","journal-title":"J Virol"},{"key":"2201_CR27","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","volume":"24","author":"PJ Bergman","year":"2006","unstructured":"Bergman PJ, Camps-Palau MA, McKnight JA et al (2006) Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24:4582\u20134585. https:\/\/doi.org\/10.1016\/j.vaccine.2005.08.027","journal-title":"Vaccine"},{"key":"2201_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/vco.12057","volume":"11","author":"JM Ottnod","year":"2013","unstructured":"Ottnod JM, Smedley RC, Walshaw R et al (2013) A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol 11:219\u2013229. https:\/\/doi.org\/10.1111\/vco.12057","journal-title":"Vet Comp Oncol"},{"key":"2201_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jsap.12613","volume":"58","author":"S Verganti","year":"2017","unstructured":"Verganti S, Berlato D, Blackwood L et al (2017) Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract 58:10\u201316. https:\/\/doi.org\/10.1111\/jsap.12613","journal-title":"J Small Anim Pract"},{"key":"2201_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.vetimm.2016.10.011","volume":"182","author":"JR Yannelli","year":"2016","unstructured":"Yannelli JR, Wouda R, Masterson TJ et al (2016) Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. Vet Immunol Immunopathol 182:95\u2013100. https:\/\/doi.org\/10.1016\/j.vetimm.2016.10.011","journal-title":"Vet Immunol Immunopathol"},{"key":"2201_CR31","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","volume":"22","author":"NJ Mason","year":"2016","unstructured":"Mason NJ, Gnanandarajah JS, Engiles JB et al (2016) Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res 22:4380\u20134390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0088","journal-title":"Clin Cancer Res"},{"key":"2201_CR32","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1016\/j.vaccine.2015.08.017","volume":"33","author":"L Marconato","year":"2015","unstructured":"Marconato L, Stefanello D, Sabattini S et al (2015) Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. Vaccine 33:5080\u20135086. https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.017","journal-title":"Vaccine"},{"key":"2201_CR33","doi-asserted-by":"publisher","first-page":"12803","DOI":"10.18632\/oncotarget.2516","volume":"5","author":"V Gabai","year":"2014","unstructured":"Gabai V, Venanzi FM, Bagashova E et al (2014) Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget 5:12803\u201312810. https:\/\/doi.org\/10.18632\/oncotarget.2516","journal-title":"Oncotarget"},{"key":"2201_CR34","first-page":"56","volume":"19","author":"S Gyorffy","year":"2005","unstructured":"Gyorffy S, Rodriguez-Lecompte JC, Woods JP et al (2005) Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 19:56\u201363","journal-title":"J Vet Intern Med"},{"key":"2201_CR35","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","volume":"110","author":"N Tatsis","year":"2007","unstructured":"Tatsis N, Fitzgerald JC, Reyes-Sandoval A et al (2007) Adenoviral vectors persist in vivo and maintain activated CD8 + T cells: implications for their use as vaccines. Blood 110:1916\u20131923. https:\/\/doi.org\/10.1182\/blood-2007-02-062117","journal-title":"Blood"},{"key":"2201_CR36","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.4049\/jimmunol.171.12.6774","volume":"171","author":"AR Pinto","year":"2003","unstructured":"Pinto AR, Fitzgerald JC, Giles-Davis W et al (2003) Induction of CD8 + T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171:6774\u20136779","journal-title":"J Immunol"},{"key":"2201_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/vr.154.15.457","volume":"154","author":"M B\u00f6hm","year":"2004","unstructured":"B\u00f6hm M, Thompson H, Weir A et al (2004) Serum antibody titres to canine parvovirus, adenovirus and distemper virus in dogs in the UK which had not been vaccinated for at least three years. Vet Rec 154:457\u2013463","journal-title":"Vet Rec"},{"key":"2201_CR38","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1128\/JVI.02497-06","volume":"81","author":"K McCoy","year":"2007","unstructured":"McCoy K, Tatsis N, Korioth-Schmitz B et al (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81:6594\u20136604. https:\/\/doi.org\/10.1128\/JVI.02497-06","journal-title":"J Virol"},{"key":"2201_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051101","author":"J Ettlin","year":"2017","unstructured":"Ettlin J, Clementi E, Amini P et al (2017) Analysis of gene expression signatures in cancer-associated stroma from canine mammary tumours reveals molecular homology to human breast carcinomas. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18051101","journal-title":"Int J Mol Sci"},{"key":"2201_CR40","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","volume":"99","author":"G Ishii","year":"2016","unstructured":"Ishii G, Ochiai A, Neri S (2016) Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99:186\u2013196. https:\/\/doi.org\/10.1016\/j.addr.2015.07.007","journal-title":"Adv Drug Deliv Rev"},{"key":"2201_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.yjmcc.2015.08.016","volume":"87","author":"J Tillmanns","year":"2015","unstructured":"Tillmanns J, Hoffmann D, Habbaba Y et al (2015) Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol 87:194\u2013203. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.08.016","journal-title":"J Mol Cell Cardiol"},{"key":"2201_CR42","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1158\/1541-7786.MCR-12-0307","volume":"10","author":"GS Karagiannis","year":"2012","unstructured":"Karagiannis GS, Poutahidis T, Erdman SE et al (2012) Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res MCR 10:1403\u20131418. https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0307","journal-title":"Mol Cancer Res MCR"},{"key":"2201_CR43","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.20122344","volume":"210","author":"EW Roberts","year":"2013","unstructured":"Roberts EW, Deonarine A, Jones JO et al (2013) Depletion of stromal cells expressing fibroblast activation protein-\u03b1 from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 210:1137\u20131151. https:\/\/doi.org\/10.1084\/jem.20122344","journal-title":"J Exp Med"},{"key":"2201_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/0300985810387447","volume":"48","author":"RC Smedley","year":"2011","unstructured":"Smedley RC, Lamoureux J, Sledge DG, Kiupel M (2011) Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms. Vet Pathol 48:32\u201340. https:\/\/doi.org\/10.1177\/0300985810387447","journal-title":"Vet Pathol"},{"key":"2201_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0092-8674(00)81363-X","volume":"87","author":"RI Montgomery","year":"1996","unstructured":"Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF\/NGF receptor family. Cell 87:427\u2013436","journal-title":"Cell"},{"key":"2201_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-065X.2009.00783.x","volume":"229","author":"G Cai","year":"2009","unstructured":"Cai G, Freeman GJ (2009) The CD160, BTLA, LIGHT\/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 229:244\u2013258. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00783.x","journal-title":"Immunol Rev"},{"key":"2201_CR47","doi-asserted-by":"publisher","first-page":"11646","DOI":"10.1128\/JVI.01550-10","volume":"84","author":"KM Stiles","year":"2010","unstructured":"Stiles KM, Whitbeck JC, Lou H et al (2010) Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition. J Virol 84:11646\u201311660. https:\/\/doi.org\/10.1128\/JVI.01550-10","journal-title":"J Virol"},{"key":"2201_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nm1704","volume":"14","author":"MO Lasaro","year":"2008","unstructured":"Lasaro MO, Tatsis N, Hensley SE et al (2008) Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 14:205\u2013212. https:\/\/doi.org\/10.1038\/nm1704","journal-title":"Nat Med"},{"key":"2201_CR49","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.4049\/jimmunol.0903808","volume":"184","author":"L DiMenna","year":"2010","unstructured":"DiMenna L, Latimer B, Parzych E et al (2010) Augmentation of primary influenza A virus-specific CD8 + T cell responses in aged mice through blockade of an immunoinhibitory pathway. J Immunol 184:5475\u20135484. https:\/\/doi.org\/10.4049\/jimmunol.0903808","journal-title":"J Immunol"},{"key":"2201_CR50","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/eji.201343751","volume":"43","author":"YD Mahnke","year":"2013","unstructured":"Mahnke YD, Brodie TM, Sallusto F et al (2013) The who\u2019s who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 43:2797\u20132809. https:\/\/doi.org\/10.1002\/eji.201343751","journal-title":"Eur J Immunol"},{"key":"2201_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4049\/jimmunol.168.1.29","volume":"168","author":"CJ Pitcher","year":"2002","unstructured":"Pitcher CJ, Hagen SI, Walker JM et al (2002) Development and homeostasis of T cell memory in rhesus macaque. J Immunol 168:29\u201343","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-018-2201-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2201-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2201-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:31:35Z","timestamp":1744176695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-018-2201-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2201"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2201-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]},"assertion":[{"value":"6 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All applicable institutional guidelines for the care and use of animals were followed. All animal experimental procedures are congruent with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 1996) and were approved by the East Tennessee Clinical Research Animal Care and Use Committee. Animal activities were conducted at East Tennessee Clinical Research, Rockwood, Tennessee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Hildegund CJ Ertl is named as an inventor on patents for the use of gD and FAP in vaccines; she holds equity in Virion Therapeutics. Lorraine H Keller holds equity in MBF Therapeutics and certain technology and patent rights have been licensed to MBF Therapeutics. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}